I believe that by Christmas we will be in the high 30's due to the impressive results and take rate that may be shown by the news in early November. I would not be surprised to see an intraday high of 40 prior to that time or a bid by Amgen to acquire this drug and then subsequent offering to their current locked-in dialysis center clients. That Amgen's drug comes off patent protection in the near future is enough reason aside and firms up their strength in this area. Additionally marketing by Affymax will be key and patients may even move over to centers currently offering their drug. This recent change in price direction is not weakness but some board shuffling. Real weakness would have been exemplified by much higher volume. This is normal and healthly. I am only wondering why Takeda has not taken much more of an ownership position, maybe they will derive their take on international prospects. Summary: Stay the course.